Physician profile
Christopher Seidler
NPI 1497729347
$18,447.48
in general payments reported to CMS, 2019-2025
49 companies · $3,495 in 2025
The $3,495 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $109 · 2021: $404 · 2022: $559 · 2023: $7,644 · 2024: $5,609 · 2025: $3,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $2,664 · Travel and Lodging: $2,206 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,856.00 |
| Food and Beverage | $2,664.19 |
| Travel and Lodging | $2,206.25 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $5,934.75 | 2023 | Yescarta |
| Regeneron Pharmaceuticals, INC. | $5,243.83 | 2023-2024 | Libtayo |
| Geron Corporation | $2,886.53 | 2025 | Imetelstat, Rytelo |
| Abbvie INC. | $839.12 | 2019-2025 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $279.13 | 2020-2025 | Lynparza, Epanova, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $268.99 | 2019-2025 | Opdivo |
| Genzyme Corporation | $207.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $200.23 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $188.43 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $163.76 | 2019-2023 | |
| Amgen INC. | $158.94 | 2019-2023 | Lumakras, Kyprolis, Nplate |
| Celgene Corporation | $156.62 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Jazz Pharmaceuticals INC. | $155.63 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $139.13 | 2021-2023 | Libtayo |
| Rigel Pharmaceuticals, INC. | $137.38 | 2020-2025 | Rezlidhia, Gavreto, Tavalisse |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Seidler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.